Evidence map›Paper›PMID 42346265›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Mustafa Seyyar, Ali Kalem, Mürsel Sali, Berkan Karabuğa, Taha Koray Sahin, Ahmet Kürşad Dişli, Alper Türkel, Berkan Karadurmuş, Ece Şahin Hafızoğlu, Nilüfer Avcı and 51 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

61 authors.

Mustafa SeyyarDepartment of Medical Oncology, Gaziantep City Hospital, Gaziantep 27470, Türkiye.ORCID 0000-0002-4841-7994
Ali KalemDepartment of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep 27310, Türkiye.ORCID 0009-0001-0937-0468
Mürsel SaliDepartment of Medical Oncology, Faculty of Medicine, Bursa Uludağ University, Bursa 16059, Türkiye.ORCID 0009-0007-2079-3350
Berkan KarabuğaDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara 06200, Türkiye.ORCID 0000-0001-5357-7610
Taha Koray SahinDepartment of Medical Oncology, Cancer Institute, Hacettepe University, Ankara 06230, Türkiye.ORCID 0000-0002-3590-0426
Ahmet Kürşad DişliDepartment of Medical Oncology, Faculty of Medicine, Erciyes University, Kayseri 38280, Türkiye.
Alper TürkelDepartment of Medical Oncology, Eskişehir City Hospital, Eskişehir 26080, Türkiye.
Berkan KaradurmuşDepartment of Medical Oncology, Gulhane Training and Research Hospital, Ankara 06010, Türkiye.ORCID 0000-0002-4821-8143
Ece Şahin HafızoğluDepartment of Medical Oncology, Faculty of Medicine, Celal Bayar University, Manisa 45030, Türkiye.ORCID 0009-0007-7753-1482
Nilüfer AvcıDepartment of Medical Oncology, School of Health Sciences Radiotherapy Program, Fenerbahçe University, Istanbul 34758, Türkiye.
Irem BilgetekinDepartment of Medical Oncology, Ankara Memorial Hospital, Ankara 06520, Türkiye.ORCID 0000-0003-1154-5850
Naziyet Köse BaytemurDepartment of Medical Oncology, Ankara Memorial Hospital, Ankara 06520, Türkiye.ORCID 0000-0002-3587-2517
Esma UguztemurDepartment of Medical Oncology, Adıyaman Training and Research Hospital, Adiyaman 02040, Türkiye.ORCID 0000-0003-1822-3870
Utku OflazoğluDepartment of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir 35360, Türkiye.
Hasibe Bilge GürDepartment of Medical Oncology, Sakarya Training and Research Hospital, Sakarya 54100, Türkiye.ORCID 0000-0001-8639-3076
İlhan HacıbekiroğluDepartment of Medical Oncology, Sakarya Training and Research Hospital, Sakarya 54100, Türkiye.
Aysun Fatma AkkuşDepartment of Medical Oncology, Faculty of Medicine, Trakya University, Edirne 22030, Türkiye.ORCID 0000-0003-3922-3845
Sernaz TopaloğluDepartment of Medical Oncology, Faculty of Medicine, Trakya University, Edirne 22030, Türkiye.ORCID 0000-0001-5387-8309
Ayberk BayramgilDepartment of Medical Oncology, SBU Umraniye Training and Research Hospital, Istanbul 34764, Türkiye.ORCID 0000-0003-1782-7808
Özgecan Dülgar KayaDepartment of Medical Oncology, SBU Umraniye Training and Research Hospital, Istanbul 34764, Türkiye.
Melike YazıcıDepartment of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41001, Türkiye.
Teoman ŞakalarDepartment of Medical Oncology, HG Hospital, Kahramanmaraş 46050, Türkiye.
Seval AkayDepartment of Medical Oncology, Izmir City Hospital, Izmir 35540, Türkiye.ORCID 0000-0002-1235-6739
Nargiz MajidovaDepartment of Medical Oncology, VM Medical Park Maltepe Hospital, Istanbul 34843, Türkiye.ORCID 0000-0002-2575-5819
Murad GuliyevDepartment of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0002-2981-8098
Özkan AlanDepartment of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0002-6635-2012
Serkan GülcüDepartment of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Türkiye.ORCID 0000-0003-0708-4940
Tülay ErenDepartment of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Türkiye.
Gökşen İnanç İmamoğluDepartment of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Türkiye.
Ali Kaan GürenDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Türkiye.ORCID 0000-0002-3562-5006
Osman KöstekDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34899, Türkiye.ORCID 0000-0002-1901-5603
Ahmet ÜnlüDepartment of Medical Oncology, Antalya Training and Research Hospital, Antalya 07100, Türkiye.
Banu OzturkDepartment of Medical Oncology, Antalya Training and Research Hospital, Antalya 07100, Türkiye.ORCID 0000-0003-0290-8787
Esra AydınDepartment of Medical Oncology, Recep Tayyip Erdoğan University Training and Research Hospital, Rize 53100, Türkiye.ORCID 0000-0003-0210-3153
Shamkhal SafarovDepartment of Medical Oncology, Başakşehir Çam and Sakura City Hospital, Istanbul 34480, Türkiye.
Bekir DoğanDepartment of Medical Oncology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul 34147, Türkiye.
Mehmet Akif TükenmezDepartment of Medical Oncology, Trabzon University Kanuni Training and Research Hospital, Trabzon 61250, Türkiye.
Teyfik DemirDepartment of Medical Oncology, Faculty of Medicine, Ondokuz Mayıs University, Samsun 55139, Türkiye.ORCID 0000-0002-9110-4280
Elif ŞahinDepartment of Medical Oncology, Kocaeli City Hospital, Kocaeli 41060, Türkiye.ORCID 0000-0002-1976-3951
Engin ErdemoğluDepartment of Medical Oncology, Medical Park Istanbul Oncology Hospital, Istanbul 34303, Türkiye.
Fatma Keskin UzundereDepartment of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakır 21280, Türkiye.ORCID 0000-0002-7881-5635
Osman BütünDepartment of Medical Oncology, Acıbadem Kent Hospital, Izmir 35630, Türkiye.
Bülent KarabulutDepartment of Medical Oncology, Acıbadem Kent Hospital, Izmir 35630, Türkiye.ORCID 0000-0002-1949-8334
Mehmet UzunDepartment of Medical Oncology, SBU Tepecik Training and Research Hospital, Izmir 35020, Türkiye.ORCID 0000-0002-8596-4233
Tuba BaydaşDepartment of Medical Oncology, Istanbul Medeniyet University Göztepe City Hospital, Istanbul 34722, Türkiye.ORCID 0000-0001-7336-4647
Elanur KaramanDepartment of Medical Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon 61080, Türkiye.ORCID 0000-0002-4264-8214
Hacı ArakDepartment of Medical Oncology, Gaziantep City Hospital, Gaziantep 27470, Türkiye.ORCID 0000-0002-2023-423X
Ferhat EkinciDepartment of Medical Oncology, Faculty of Medicine, Celal Bayar University, Manisa 45030, Türkiye.ORCID 0000-0002-9317-942X
Musa Barış AykanDepartment of Medical Oncology, Gulhane Training and Research Hospital, Ankara 06010, Türkiye.ORCID 0000-0001-7538-9119
İsmail ErtürkDepartment of Medical Oncology, Gulhane Training and Research Hospital, Ankara 06010, Türkiye.
Deniz Can GuvenDepartment of Medical Oncology, Cancer Institute, Hacettepe University, Ankara 06230, Türkiye.ORCID 0000-0002-6924-9467
Adem DeligönülDepartment of Medical Oncology, Faculty of Medicine, Bursa Uludağ University, Bursa 16059, Türkiye.ORCID 0009-0001-3931-0191
Cengiz KaraçinDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara 06200, Türkiye.
Öztürk AteşDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara 06200, Türkiye.ORCID 0000-0003-0182-3933
Mevlüde İnançDepartment of Medical Oncology, Faculty of Medicine, Erciyes University, Kayseri 38280, Türkiye.
Havva YeşilDepartment of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep 27310, Türkiye.ORCID 0000-0002-7870-8741
Sercan AksoyDepartment of Medical Oncology, Cancer Institute, Hacettepe University, Ankara 06230, Türkiye.ORCID 0000-0003-4984-1049
Tolga KöşeciDepartment of Medical Oncology, Faculty of Medicine, Cukurova University Balcalı Hospital, Adana 01330, Türkiye.
İlker Nihat ÖktenDepartment of Medical Oncology, Istanbul Medeniyet University Göztepe City Hospital, Istanbul 34722, Türkiye.ORCID 0000-0003-2360-3392
Hasan Çağrı YıldırımDepartment of Medical Oncology, Faculty of Medicine, Ege University, Izmir 35100, Türkiye.ORCID 0000-0003-3060-377X
Devrim ÇabukDepartment of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41001, Türkiye.ORCID 0000-0002-7871-6311

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Germline BRCA1/2-mutated (gBRCAm) hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is a biologically distinct subset in which the efficacy of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors remains incompletely characterized. We evaluated real-world outcomes and prognostic factors in a multicenter retrospective Turkish cohort treated with a CDK4/6 inhibitor plus endocrine therapy (June 2020-September 2025). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier and Cox methods. Among 121 patients, 30 (24.8%) had BRCA1, 88 (72.7%) had BRCA2, and three (2.5%) had dual mutations; 66.9% received first-line therapy, with ribociclib in 69.4% and palbociclib in 29.8%. Objective response rate was 69.4% and the clinical benefit rate was 82.6%. Median PFS was 17.0 months and OS 47.0 months. PFS was numerically longer in BRCA1 than in BRCA2 carriers (25.0 vs. 14.0 months), although the difference was not statistically significant in the pairwise comparison (HR 1.50, 95% CI 0.88-2.56; log-rank

Indexed as

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsAdultAgedAminopyridinesBRCA1 ProteinBRCA2 ProteinErb-b2 Receptor Tyrosine KinasesFemaleGerm-Line MutationHumansMiddle AgedPiperazinesPurinesAminopyridinesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Erb-b2 Receptor Tyrosine KinasesPiperazinesProtein Kinase InhibitorsPurinesReceptors, EstrogenReceptors, ProgesteroneribociclibBRCA mutationCDK4/6 inhibitorshormone receptor-positivemetastatic breast cancerpalbociclibreal-world studyribociclib

Identifiers

PMID42346265
PMCPMC13298008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.